0001628280-24-034481.txt : 20240802 0001628280-24-034481.hdr.sgml : 20240802 20240802172246 ACCESSION NUMBER: 0001628280-24-034481 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240730 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 241172286 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 8-K 1 ovid-20240730.htm 10-Q ovid-20240730
0001636651false00016366512024-07-302024-07-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2024
OVID THERAPEUTICS INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware001-3808546-5270895
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
   
441 Ninth Avenue, 14th Floor
New York, New York
10001
(Address of Principal Executive Offices)
  
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 646-661-7661
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, par value $0.001 per share  OVID The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐


Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 27, 2024, Ovid Therapeutics Inc. (the “Company”) announced that Thomas Perone, the Company’s former General Counsel, Chief Compliance Officer and Corporate Secretary, would be departing from the Company in those roles, effective as of July 11, 2024 (the “Separation Date”) in connection with a workforce reduction. On July 30, 2024, the Company entered into a consulting services agreement with Mr. Perone (the “Consulting Agreement”), which establishes the terms of the consulting and transition arrangement with Mr. Perone that was previously disclosed. Pursuant to the Consulting Agreement, Mr. Perone will consult for the Company for a period of time to transition his duties. The Consulting Agreement is effective as of the Separation Date and shall continue until January 31, 2025, unless otherwise terminated earlier by either party (the “Consulting Period”).
As consideration for the consulting services under the Consulting Agreement, Mr. Perone will be eligible to receive a monthly consulting fee payable for up to a total maximum of $55,000 over the course of the Consulting Period and his equity awards that were outstanding as of the Separation Date shall continue to vest during the Consulting Period. In addition, the Consulting Agreement provides for post-termination restrictive covenants, including non-solicitation restrictions that will continue until the one year anniversary following the termination of the Consulting Agreement.
The foregoing description of the Consulting Agreement is not complete and is qualified in its entirety by reference to the Consulting Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OVID THERAPEUTICS INC.
  
  
By:  /s/ Jeffrey Rona
  
Jeffrey Rona
  
Chief Business and Financial Officer
Dated: August 2, 2024

 EX-101.SCH 2 ovid-20240730.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ovid-20240730_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Written Communications Written Communications Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 ovid-20240730_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Jul. 30, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 30, 2024
Entity Registrant Name OVID THERAPEUTICS INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38085
Entity Tax Identification Number 46-5270895
Entity Address, Address Line One 441 Ninth Avenue
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001
City Area Code 646
Local Phone Number 661-7661
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol OVID
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001636651
Amendment Flag false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.ovidrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ovid-20240730.htm ovid-20240730.xsd ovid-20240730_lab.xml ovid-20240730_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ovid-20240730.htm": { "nsprefix": "ovid", "nsuri": "http://www.ovidrx.com/20240730", "dts": { "inline": { "local": [ "ovid-20240730.htm" ] }, "schema": { "local": [ "ovid-20240730.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "ovid-20240730_lab.xml" ] }, "presentationLink": { "local": [ "ovid-20240730_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://www.ovidrx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovid-20240730.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovid-20240730.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.ovidrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001628280-24-034481-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-034481-xbrl.zip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end XML 15 ovid-20240730_htm.xml IDEA: XBRL DOCUMENT 0001636651 2024-07-30 2024-07-30 0001636651 false 8-K 2024-07-30 OVID THERAPEUTICS INC. DE 001-38085 46-5270895 441 Ninth Avenue 14th Floor New York NY 10001 646 661-7661 false false false false Common Stock, par value $0.001 per share OVID NASDAQ false false